Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. | LitMetric

A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. | LitMetric

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Ali T Taher Zeynep Karakas Elena Cassinerio Noppadol Siritanaratkul Antonis Kattamis Aurelio Maggio Stefano Rivella Norbert Hollaender Bruyère Mahuzier Brian Gadbaw Yesim Aydinok

Blood

Ege University Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey.

Published: January 2018

Download full-text PDF
Source

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757682 PMC
http://dx.doi.org/10.1182/blood-2017-06-790121 DOI Listing

Publication Analysis

Top Keywords

efficacy safety

4

safety ruxolitinib

4

ruxolitinib regularly

4

regularly transfused

4

transfused patients

4

patients thalassemia

4

thalassemia phase

4

phase study

4

efficacy

1

ruxolitinib

1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!